Market Place
Sourcing Support
Heat Biologics Completes Name Change to NightHawk Biosciences
03 May 2022 //
GLOBENEWSWIRE
NightHawk flies into national stockpile deal with Canadian govt for anthrax drug
27 Apr 2022 //
ENDPTS
Heat Biologics Completes Acquisition of Elusys Therapeutics
20 Apr 2022 //
GLOBENEWSWIRE
Heat Biologics Announces Planned Name Change to NightHawk Biosciences
19 Apr 2022 //
GLOBENEWSWIRE
Heat Biologics` Scorpion Subsidiary Plans New Biomanufacturing Facility
18 Apr 2022 //
GLOBENEWSWIRE
Heat Biologics to Host Planned Investor and Media Livestream Event
18 Apr 2022 //
GLOBENEWSWIRE
Heat Biologics Announces Planned Investor and Media Livestream Event
14 Apr 2022 //
GLOBENEWSWIRE
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
25 Mar 2022 //
GLOBENEWSWIRE
Heat Biologics Appoints Greg Burel to its Biothreat Advisory Board
23 Mar 2022 //
GLOBENEWSWIRE
Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation
12 Jan 2022 //
GLOBENEWSWIRE
Heat Biologics Appoints SVP of Product Development & Portfolio Strategy
06 Oct 2021 //
CONTRACTPHARMA
Heat Biologics CEO to Present at Cantor Fitzgerald Global Healthcare Conference
15 Sep 2021 //
GLOBENEWSWIRE
Heat Biologics to Provide Corporate Update
30 Aug 2021 //
GLOBENEWSWIRE
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
26 Aug 2021 //
GLOBENEWSWIRE
Heat Biologics adds Former US Senator Mark Pryor to Biothreat Advisory Board
23 Aug 2021 //
GLOBENEWSWIRE
Heat Biologics Announces Formation of Biothreat Advisory Board
18 Aug 2021 //
GLOBENEWSWIRE
Heat Biologics goes back to San Antonio to build a research facility
11 Aug 2021 //
ENDPTS
Heat Biologics Announces Groundbreaking for New San Antonio Facility
09 Aug 2021 //
GLOBENEWSWIRE
Heat Biologics Announces Groundbreaking for New San Antonio Facility
09 Aug 2021 //
GLOBENEWSWIRE
Heat Biologics Joins Russell Microcap® Index
28 Jun 2021 //
GLOBENEWSWIRE
Heat Biologics Announces Significant Expansion of R&D & PreClinical Capabilities
23 Jun 2021 //
GLOBENEWSWIRE
Heat Biologics records biggest one-day gain in over four months
10 Jun 2021 //
SEEKING ALPHA
Heat Biologics Announces Promising Survival Data of HS-110 at ASCO 2021
20 May 2021 //
GLOBENEWSWIRE
Acceleron Presents Interim Results from the Open-label of the PULSAR Phase 2
18 May 2021 //
BUSINESSWIRE
Heat Biologics Provides First Quarter 2021 Business Update; Reports
05 May 2021 //
GLOBENEWSWIRE
Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating
13 Apr 2021 //
GLOBNEWSWIRE
Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110
09 Feb 2021 //
PRESS RELEASE
Heat Biologics Commences Manufacturing Process for ZVX-60
19 Jan 2021 //
PRESS RELEASE
Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19
16 Dec 2020 //
PRESS RELEASE
Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy
07 Oct 2020 //
NASDAQ
Heat Biologics Issued Key Patent on Combination Platform Therapy
02 Sep 2020 //
PRESS RELEASE
Heat Biologics Highlights Importance of T cell Immunity to Prevent COVID-19
05 Aug 2020 //
ACCESSWIRE
Heat Biologics Announces First Patient Treated in First-in-Human Trial of PTX-35
22 Jun 2020 //
PRESS RELEASE
Heat Biologics Announces FDA Clearance of (IND) Application for PTX-35
08 Jun 2020 //
PRESS RELEASE
Heat Biologics Presents Positive Survival Benefit for HS-110 with Nivolumab
29 May 2020 //
HEATBIO
Positive Survival Data from Phase 2 Lung Cancer Trial Accepted for ASCO
14 May 2020 //
HEATBIO
Heat Biologics Clinical Update; Reports Continued Progress Advancing HS-110
11 May 2020 //
YAHOO
Heat Biologics Announces Research Collaboration with University of Miami
05 Mar 2020 //
HEATBIO
Heat Biologics Announces First Patient Dosed in the First Ph 1 Trial of HS-130
16 Dec 2019 //
PRESS RELEASE
